Wang Z, Zhou W, Srivastava T, La Rosa C, Mandarino A, Forman SJ, Zaia JA, Britt WJ, Diamond DJ. A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector. Virology, 377(2): 379-390, 2008
Yue Y, Wang Z, Abel K, Li J, Strelow L, Mandarino A, Eberhardt MK, Schmidt KA, Diamond DJ, Barry PA. Evaluation of recombinant modified vaccinia Ankara virus-based rhesus CMV in rhesus macaques. MMI, 197(2):117-123, 5/2008.
La Rosa C, Krishnan A, Longmate J, Martinez J, Manchanda P, Lacey SF, Limaye AP and Diamond DJ. PD-1 expression in liver transplant recipients as a prognostic indicator of CMV disease. J. Infectious Diseases, 197(1):25-33, 2008.
Song G-Y, Gibson G, Haq W, Huang ECC, Srivastava T, Hollstein M, Daftarian P, Wang Z, Diamond DJ, and Ellenhorn J. An MVA vaccine overcomes tolerance to human p53 in mouse and man. Cancer Immunology & Immunotherapy, 56(8):1193-1205, 2007.
La Rosa C, Limaye AP, Krishnan A, Longmate J and Diamond DJ. Longitudinal assessment of CMV-specific immune responses in liver transplant recipients at high risk for late CMV disease. J. of Infectious Diseases, 195:633-644,2007. Editorial Commentary by Boeckh and Riddell in same issue (195:615-617).
Khanna, R and Diamond, DJ. Human cytomegalovirus vaccine: Time to look for alternative options. Trends in Molecular Medicine. 12(1):26-33, 2006.
P Daftarian, R Sharan, S Ali, W Haq, J Longmate, J Termini, & DJ Diamond. Novel Epitope Peptide Fusions Conjugated with ssDNA Confer Enhanced Vaccine Properties Including HIV Recognition.Vaccine, 23(25):3453-3468, 2005.
P Daftarian, S Ali, GY Song, M Faynsod, J Longmate, DJ Diamond, JDI Ellenhorn. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer Res, 64(15):5407-5414, 2004.
S Lacey, DJ Diamond, and JA Zaia. Assessment of Cellular Immunity to Human Cytomegalovirus in Recipients of Allogeneic Stem Cell Transplants. BBMT, 10(7):433-447, 2004.
Z Wang, C La Rosa, S Mekhoubad, SF Lacey, M Villacres, S Markel, J Longmate, JDI Ellenhorn, RF Siliciano, C Buck, WJ Britt, and DJ Diamond. Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T-cells. Blood,104(3):847-856, 2004.
Z Wang, C La Rosa, R Maas, H Ly, J Brewer, S Mekhoubad, P Daftarian, J Longmate, WJ Britt, and DJ Diamond. Recombinant MVA expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of CMV. J. of Virology, 78(8): 3965-3976, 2004
L Gibson, G Piccinini, D Lilleri, MG Revello, Z Wang, S Markel, DJ Diamond, K Luzuriaga. Human cytomegalovirus proteins pp65 and IE1 are common targets for CD8+ T-cell responses in children with congenital or postnatal human CMV infection., J. Immunol., 172(4): 2256-2264, 2004
P Daftarian, S Ali, R Sharan, SF Lacey, C LaRosa, J Longmate, C Buck, RF Siliciano, and DJ Diamond. Immunization with TH-CTL fusion peptide and CpG DNA in transgenic HLA A2 mice induces recognition of HIV-infected T cells and clears a vaccinia virus challenge. J. Immunol, 171(8): 4028-39, 2003.
J Espenschied, J Lamont, J Longmate, S Pendas, Z Wang, DJ Diamond, and JDI Ellenhorn. CTLA-4 blockade enhances the therapeutic effect of attenuated poxvirus vaccine targeting p53 in established murine tumor model. J. Immunol.,170:3401-3407, 2003.
C La Rosa, Z Wang, J Brewer, S Lacey, M Villacres, R Sharan, R Krishnan, M Crooks, S Markel, R Maas, and DJ Diamond. Pre-clinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood, 100(10):3681-3689, 2002.
This is a partial list. Full publications list available upon request. Information on this page may be self-reported and subject to change at any time. Last updated: 07/08.
